Methods of administering antibodies that bind interleukin 13
Patent Information
- Application Number
- HK62026126964
- Authority / Receiving Office
- HK · HK
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-03-04
- Filing Date
- 2026-08-03
- Publication Date
- 2026-09-11
Smart Images

Figure 00000000_0000_ABST
Abstract
Description
Abstract This article describes the administration and use of antibodies that bind to interleukin-13 (IL-13). In some respects, this article describes methods for inhibiting the biological activity of IL-13. In some respects, the antibodies and methods described herein are intended for the treatment of inflammatory conditions or diseases.
Claims
Claims 1. A method of treating atopic dermatitis in a patient in need thereof, the method comprising subcutaneously administering to the patient: a) one to five or more induction doses, each selected from 100 mg, 125 mg, 150 mg, 180 mg, 200 mg, 250 mg, 300 mg, 360 mg, 400 mg, 450 mg, 600 mg, 720 mg, 800 mg, 900 mg, 1080 mg, or 1200 mg of an anti-IL-13 antibody; and b) one or more maintenance doses administered starting at about 4-17 weeks or more after the first induction dose; wherein the maintenance dose is 150 mg, 180 mg, 200 mg, 250 mg, 300 mg, 360 mg, 400 mg, 450 mg, 600 mg, 800 mg, 1080 mg, or 1200 mg of the anti-IL-13 antibody; and wherein the anti-IL-13 antibody comprises a heavy chain variable region (VH) comprising an amino acid sequence having at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) sequence identity to the sequence set forth in SEQ ID NO: 3 and a light chain variable region (VL) comprising an amino acid sequence having at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) sequence identity to the sequence set forth in SEQ ID NO:
39.
2. The method of claim 1, further comprising administering a loading dose prior to the one to five or more induction doses, wherein the loading dose is 2 times the induction dose.
3. The method of claim 1, wherein the one or more maintenance doses are administered about 4-16 weeks or 12-16 weeks after the first induction dose.
4. The method of any one of claims 1-3, where the first induction dose is 150 mg, 300 mg, 360 mg, or 600 mg.
5. The method of any one of claims 1-4, comprising administering a second, third, fourth, and / or fifth induction dose of 300 mg or 360 mg of the anti-IL-13 antibody.
6. The method of claim 5 wherein the second induction dose is administered about 2 to about 16 weeks after the first induction dose.
7. The method of claim 5, wherein the second induction dose is administered about two or about eight weeks after the first induction dose.
8. The method of any one of claims 1-4, comprising administering a second, third, fourth, and / or fifth induction dose of 600 mg of the anti-IL-13 antibody.
9. The method of claim 8, wherein the second induction dose is administered about 2 to about 16 weeks after the first induction dose.
10. The method of claim 8, wherein the second induction dose is administered about 2 weeks after the first induction dose.
11. The method of any one of claims 1-10, wherein the maintenance dose is 150 mg, 200 mg, 300 mg, 360 mg, 400 mg, 600 mg, or 800 mg and is administered every 3 months, every 12 weeks, or 4 times a year.
12. The method of any one of claims 1-10, wherein the maintenance dose is 150 mg, 200 mg, 300 mg, 360 mg, 400 mg, 600 mg, or 800 mg and is administered every 2 months or every 8 weeks.
13. The method of any one of claims 1-10, wherein the maintenance dose is 150 mg, 200 mg, 300 mg, 360 mg, 400 mg, 600 mg, or 800 mg and is administered every 16 weeks or three times a year.
14. The method of any one of claims 1-10, wherein the maintenance dose is 150 mg, 200 mg, 300 mg, 360 mg, 400 mg, 600 mg, or 800 mg and is administered every 20 weeks.
15. The method of any one of claims 1-10, wherein the maintenance dose is 150 mg, 200 mg, 300 mg, 360 mg, 400 mg, 600 mg, or 800 mg and is administered every 6 months or twice a year.
16. The method of any one of claims 1-10, wherein the maintenance dose is 150 mg, 200 mg, 300 mg, 360 mg, 400 mg, 600 mg, or 800 mg and is administered once a year.
17. The method of any one of claims 1-10, wherein the maintenance dose is 300 mg, 360 mg, or 600 mg and is administered every 3 months, 12 weeks, or 4 times a year.
18. The method of any one of claims 1-10, wherein the maintenance dose is 300 mg, 360 mg, or 600 mg and is administered every 2 months or 8 weeks.
19. The method of any one of claims 1- 10, wherein the maintenance dose is 300 mg, 360 mg, or 600 mg and is administered every 16 weeks or three times a year.
20. The method of any one of claims 1-10, wherein the maintenance dose is 300 mg, 360 mg, or 600 mg and is administered every 20 weeks.
21. The method of any one of claims 1-10, wherein the maintenance dose is 300 mg, 360 mg, or 600 mg and is administered every 6 months or twice a year.
22. The method of any one of claims 1-10, wherein the maintenance dose is 300 mg, 360 mg, or 600 mg and is administered once a year.
23. The method of any one of claims 1-22, wherein each unit dose is administered as composition comprising 150 mg / mL, 180 mg / mL, or 200 mg / mL of the anti-IL-13 antibody.
24. The method of claim 23, wherein the unit dose has an extractable volume of about 2 mL, about 2.25 mL, or about 2.7 mL.
25. The method of any one of claims 1-24, wherein the anti-IL-13 antibody is administered by an autoinjector.
26. The method of any one of claims 1-24, wherein the anti-IL-13 antibody is administered by a pre-filled syringe.
27. The method of any one of claims 1-26, wherein the patient has been diagnosed with moderate-to-severe atopic dermatitis.
28. The method of any one of claims 1-27, wherein the patient has had moderate-to-severe atopic dermatitis for at least one year.
29. The method of any one of claims 1-28, wherein the patient has one or more of: (a) an Eczema Area and Severity Index Score (EASI) of ≥10, (b) an Investigator Global Assessment (IGA) score of ≥3 and (c) a body surface area (BSA) of ≥10%.
30. The method of any one of claims 1-29, further comprising determining one or more of the following characteristics of the patient at baseline and during and after the induction period: Eczema Area and Severity Index (EASI), Investigator Global Assessment (IGA), Body Surface Area (BSA), Pruritus Numerical Rating Scale (NRS), Sleep loss scale, SCORing Atopic Dermatitis (SCORAD), Patient Oriented Eczema Measure (POEM), Dermatology Life Quality Index (DLQI).
31. A method of treating atopic dermatitis in a patient in need thereof, the method comprising: subcutaneously administering to the patient an anti-IL-13 antibody for an induction period of 4 to 17 weeks, wherein, during the induction period, the anti-IL-13 antibody is administered once or twice at a loading dose of from about 100 mg to about 1200 mg or a dose listed in any one of Tables 11-13, and, optionally, at least once at a dose that is at one-half or one-quarter of the loading dose; and subcutaneously administering to the patient the anti-IL-13 antibody at a dose of from about 100 mg to about 1200 mg or a dose listed in Table 14 for a maintenance period; wherein the anti-IL-13 antibody comprises a heavy chain variable region (VH) comprising an amino acid sequence having at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) sequence identity to SEQ ID NO: 3 and a light chain variable region (VL) comprising an amino acid sequence at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) sequence identity to SEQ ID NO: 39, wherein the VH comprises a HCDR1 comprising SEQ ID NO: 58, SEQ ID NO: 68, or SEQ ID NO: 85; a HCDR2 comprising SEQ ID NO: 100, SEQ ID NO: 104, or SEQ ID NO: 108; and a HCDR3 comprising SEQ ID NO: 112 or SEQ ID NO: 130; and the VL comprises a LCDR1comprising SEQ ID NO: 141 or SEQ ID NO: 149; a LCDR2 comprising SEQ ID NO: 153 or SEQ ID NO: 164, and a LCDR3 comprising SEQ ID NO:
165.
32. The method of claim 31, wherein the loading dose is about 100 mg, 150 mg, 180 mg, 200 mg, 300 mg, 360 mg, 400 mg, 450 mg, 600 mg, 720 mg, 800 mg, 900 mg, 1080 mg, or 1200 mg.
33. The method of claim 31 or 32, wherein, during the induction period, the loading dose is administered at week 0 and week 2.
34. The method of claim 31 or 32, wherein, during the induction period, the loading dose is administered at week 0 and week 4.
35. The method of claim 31 or 32, wherein, during the induction period, the loading dose is administered at week 0 and week 8.
36. The method of claim 31 or 32, wherein, during the induction period, the loading dose is administered at week 0 and week 12.
37. The method of any one of claims 31-36, wherein, during the induction period, the one- half or one-quarter dose is administered at weeks 8, 12, and 16.
38. The method of any one of claims 31-36, wherein, during the induction period, the one- half or one-quarter dose is administered at weeks 4, 8, 12, and 16.
39. The method of any one of claims 31-36, wherein, during the induction period, the one- half or one-quarter dose is administered at weeks 4 and 12.
40. The method of any one of claims 31-36, wherein, during the induction period, the one- half or one-quarter dose is administered at weeks 2, 4, and 12.
41. The method of any one of claims 31-36, wherein, during the induction period, the one- half or one-quarter dose is administered at weeks 2 and 12.
42. The method of any one of claims 31-36, wherein, during the induction period, the one- half or one-quarter dose is administered at week 12.
43. The method of any one of claims 31-36, wherein, during the induction period, the one- half or one-quarter dose is administered at weeks 8 and 16.
44. The method of any one of claims 31-36, wherein, during the induction period, the one- half or one-quarter dose is administered at week 16.
45. The method of any one of claims 31-36, wherein, during the induction period, the one- half or one-quarter dose is administered at weeks 4 and 14.
46. The method of any one of claims 31-36, wherein, during the induction period, the one- half or one-quarter dose is administered at week 14.
47. The method of any one of claims 31-36, wherein, during the induction period, the one- half or one-quarter dose is administered at weeks 2, 4, and 14.
48. The method of any one of claims 31-47, wherein the maintenance dose is 100 mg, 150 mg, 180 mg, 200 mg, 300 mg, 360 mg, 400 mg, 450 mg, 600 mg, 720 mg, 800 mg, or 900 mg.
49. The method of any one of claims 31-48, wherein, during the maintenance period, the anti-IL-13 antibody is administered 3 months, every 12 weeks, or 4 times a year.
50. The method of any one of claims 31-48, wherein, during the maintenance period, the anti-IL-13 antibody is administered every 2 months or 8 weeks.
51. The method of any one of claims 31-48, wherein, during the maintenance period, the anti-IL-13 antibody is administered every 16 weeks or three times a year.
52. The method of any one of claims 31-48, wherein, during the maintenance period, the anti-IL-13 antibody is administered every 20 weeks.
53. The method of any one of claims 31-48, wherein, during the maintenance period, the anti-IL-13 antibody is administered every 6 months or twice a year.
54. The method of any one of claims 31-48, wherein, during the maintenance period, the anti-IL-13 antibody is administered once a year.
55. The method of any one of claims 31-54, wherein the anti-IL-13 antibody comprises a heavy chain variable region (VH) comprising an amino acid sequence as set forth in SEQ ID NO: 3 and a light chain variable region (VL) comprising an amino acid sequence as set forth in SEQ ID NO:
39.
55. A method of treating atopic dermatitis in a patient in need thereof, the method comprising subcutaneously administering to the patient: a) two loading doses of 720 mg of an anti-IL-13 antibody prior to two induction doses; b) two induction doses of 360 mg of the anti-IL-13 antibody; and c) one or more maintenance doses of 360 mg of the anti-IL-13 antibody administered starting at about 12 weeks or more after the first induction dose; and wherein the anti-IL-13 antibody comprises a heavy chain variable region (VH) comprising an amino acid sequence as set forth in SEQ ID NO: 3 and a light chain variable region (VL) comprising an amino acid sequence as set forth in SEQ ID NO:
39.
56. The method of claim 55, wherein the second loading dose is administered about 2 weeks after the first loading dose.
57. The method of claim 55 or 56, wherein the first induction dose is administered about 2 weeks after the second loading dose.
58. The method of any one of claims 55-57, wherein the second induction dose is administered about 8 weeks after the first induction dose.
59. The method of any one of claims 55-58, wherein the maintenance dose is administered every 3 months.
60. The method of any one of claims 55-58, wherein the maintenance dose is administered every 6 months.
61. A method of treating atopic dermatitis in a patient in need thereof, the method comprising subcutaneously administering to the patient: a) a loading dose of 720 mg of an anti-IL-13 antibody prior to two induction doses; b) two induction doses of 360 mg of the anti-IL-13 antibody; and c) one or more maintenance doses of 360 mg of the anti-IL-13 antibody administered starting at about 12 weeks or more after the first induction dose; and wherein the anti-IL-13 antibody comprises a heavy chain variable region (VH) comprising an amino acid sequence as set forth in SEQ ID NO: 3 and a light chain variable region (VL) comprising an amino acid sequence as set forth in SEQ ID NO:
39.
62. The method of claim 61, wherein the first induction dose is administered about 4 weeks after the loading dose.
63. The method of any one of claims 61-62, wherein the second induction dose is administered about 8 weeks after the first induction dose.
64. The method of any one of claims 61-63, wherein the maintenance dose is administered every 3 months.
65. The method of any one of claims 61-64, wherein the maintenance dose is administered every 6 months.
66. A method of treating atopic dermatitis in a patient in need thereof, the method comprising subcutaneously administering to the patient: a) a loading dose of 360 mg of an anti-IL-13 antibody prior to two induction doses; b) two induction doses of 180 mg of the anti-IL-13 antibody; and c) one or more maintenance doses of 180 mg of the anti-IL-13 antibody administered starting at about 12 weeks or more after the first induction dose; and wherein the anti-IL-13 antibody comprises a heavy chain variable region (VH) comprising an amino acid sequence as set forth in SEQ ID NO: 3 and a light chain variable region (VL) comprising an amino acid sequence as set forth in SEQ ID NO: 39.
67. The method of claim 66, wherein the first induction dose is administered about 4 weeks after the loading dose.
68. The method of any one of claims 66-67, wherein the second induction dose is administered about 8 weeks after the first induction dose.
69. The method of any one of claims 66-68, wherein the maintenance dose is administered every 3 months.
70. The method of any one of claims 66-69, wherein the maintenance dose is administered every 6 months.
71. The method of any one of claims 66-70, wherein each dose is administered as a composition comprising 150 mg / mL, 180 mg / mL, or 200 mg / mL of the anti-IL-13 antibody.
72. The method of claim 71, wherein the composition is a unit dose with an extractable volume of 2 mL, 2.25, or 2.7 mL.
73. The method of claim 72, wherein the composition is a unit dose with an extractable volume of 2 mL.
74. The method of any one of claims 31-73, wherein the patient has been diagnosed with moderate-to-severe atopic dermatitis.
75. The method of any one of claims 31-74, wherein the patient has had moderate-to-severe atopic dermatitis for at least one year.
76. The method of any one of claims 31-75, wherein the patient has one or more of: (a) an Eczema Area and Severity Index Score (EASI) of ≥10, (b) an Investigator Global Assessment (IGA) score of ≥3 and (c) a body surface area (BSA) of ≥10%.
77. The method of any one of claims 31-76, further comprising determining one or more of the following characteristics of the patient at baseline and during and after the induction period: Eczema Area and Severity Index (EASI), Investigator Global Assessment (IGA), Body Surface Area (BSA), Pruritus Numerical Rating Scale (NRS), Skin Pain Numerical Rating Scale (SP-NRS), Sleep loss scale, SCORing Atopic Dermatitis (SCORAD), Patient Oriented Eczema Measure (POEM), Dermatology Life Quality Index (DLQI), Asthma Control Questionnaire 5-item version (ACQ-5), Sino-nasal Outcome Test 22-item version (SNOT-22).
78. A composition comprising 150 mg / mL, 180 mg / mL, or 200 mg / mL of an anti-IL-13 antibody, wherein the anti-IL-13 antibody comprises a heavy chain variable region (VH) comprising an amino acid sequence as set forth in SEQ ID NO: 3 and a light chain variable region (VL) comprising an amino acid sequence as set forth in SEQ ID NO: 39.
79. The composition of claim 78, wherein the composition is a unit dose with an extractable volume of 2 mL, 2.25 mL, or 2.7 mL.
80. The composition of claim 79, wherein the composition is a unit dose with an extractable volume of 2 mL.
81. An autoinjector configured to deliver a composition comprising 150 mg / mL, 180 mg / mL, or 200 mg / mL of an anti-IL-13 antibody, wherein the anti-IL-13 antibody comprises a heavy chain variable region (VH) comprising an amino acid sequence as set forth in SEQ ID NO: 3 and a light chain variable region (VL) comprising an amino acid sequence as set forth in SEQ ID NO:
39.
82. The autoinjector of claim 81, wherein the composition is a unit dose with an extractable volume of 2 mL 2.25 mL, or 2.7 mL.
83. The method, composition, or autoinjector of any of the preceding claims, further comprising a heavy chain constant region of SEQ ID NO: 439 or SEQ ID NO: 624 or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity thereto.
84. The method, composition, or autoinjector of any of the preceding claims, further comprising a light chain constant region of SEQ ID NO: 469 or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity thereto.
